The emergence of immune checkpoint targets, such as programmed death-1 (PD-1) and programmed death-ligand-1 (PD-L1) provides another therapeutic strategy for metastatic RCC [7], perhaps more compelling than targeted therapy agents [8], which emphasizes the importance of the tumor immune status on the outcome of RCC patients. The gene discussed is CD274; the disease is renal cell carcinoma.